We examined the prognosis of liver cirrhosis (LC) patients with and without portal hypertension (PHT) and muscle volume loss (MVL).
INTRODUCTION

P ATIENTS WITH CHRONIC liver disease (CLD) (chronic hepatitis [CH] and liver cirrhosis [LC]) are often complicated with muscle volume loss (MVL). Several reports have noted that MVL is an important prognostic
factor in CLD patients with or without hepatocellular carcinoma (HCC) who have been treated with resection, 1 liver transplantation, [2] [3] [4] [5] or sorafenib. 6 Moreover, MVL has recently been reported as a common complication in patients with CLD. 7, 8 In addition, esophagogastric varices (EGV) are often complicated with other conditions such as LC because of the presence of portal hypertension (PHT), which is known to be an independent risk factor for prognosis in LC patients with early HCC. 9 However, few studies have examined the clinical importance of MVL or EGV as a result of PHT in regard to the prognosis of LC patients. In the present study, we examined the prognosis of LC patients with and without PHT and MVL.
METHODS
Patients
O NE THOUSAND AND twenty-two patients with CLD underwent upper gastrointestinal endoscopy and computed tomography (CT) examinations at Ehime Prefectural Central Hospital (Matsuyama, Japan). After excluding patients with HCC beyond the Milan criteria (3 cm/three tumors or 5 cm/single tumor), 10 those with past history of HCC, and those with CH or decompensated status (Child-Pugh class C), 814 outpatients were subjected to propensity matching to select pairs with and without PHT. All cases of HCC were treatment naïve.
To reduce the confounding effects of covariates, we undertook propensity scoring for matching patients with PHT to those without PHT using logistic regression with the following 11 independent variables: age (<65 or ≥65 years), gender (male or female), LC etiology (hepatitis C virus [HCV] or others), Child-Pugh class (A or B), albumin level (≤3.5 or >3.5 g/dL), total bilirubin level (<1.0 or ≥1.0 mg/dL), platelet count (<10 or ≥10 ×10 4 cells/μL), aspartate aminotransferase level (AST; <40 or ≥40 IU/L), alanine aminotransferase level (ALT; <40 or ≥40 IU/L), HCC within Milan criteria (positive or negative), and MVL (positive or negative). The calculated propensity scores ranged from 0.08936 to 0.84907 (median, 0.43124) in each group, which were then rounded to two decimal places. We then carried out oneto-one matching of patients based on their propensity scores to the second decimal place. The P-value of the calculated propensity score, determined with a HosmerLemeshow test, was 0.252. The area under the curve of the receiver operating characteristic-calculated propensity score was 0.737 (95% confidence interval [CI], 0.723-0.886). After excluding pairs of patients with HCC who had received non-curative treatment for HCC (transcatheter chemoembolization and supportive care), 173 patients with PHT (PHT group) and 173 without PHT (non-PHT group) were finally analyzed. We examined the influences of PHT and MVL on prognosis and overall survival (OS) in these LC patients matched by propensity scores.
Definition of PHT, evaluation and treatment of EGV
Patients positive for significant EGV were defined as PHT. Esophagogastric varices were classified into three types, small straight (grade 1), enlarged tortuous (grade 2), and large coil-shaped (grade 3), according to the classification of the Japan Gastroenterological Endoscopy Society, and those with a grade 2 or more were classified as clinically significant. When red colored spots or bleeding were pointed out on varices or enlargement of varices was confirmed in serial routine upper endoscopic examinations in those with significant EGV, endoscopic treatment (endoscopic injection sclerotherapy [EIS], 11 or endoscopic variceal ligation [EVL] performed in combination with argon plasma coagulation) 12 , or balloonoccluded retrograde transvenous obliteration (BRTO) 13 was carried out to prevent bleeding.
Evaluation of muscle volume
Computed tomography examination for screening of HCC was undertaken within 6 months of upper gastrointestinal endoscopy. Muscle volume loss was defined using a previously reported index (psoas muscle area at the middle-L3 level in CT findings , which was obtained from findings of a heathy Japanese cohort. 7 Muscle area at the middle-L3 level was manually calculated from CT findings using a software package (Centricity Web DX version 3.7.3.6417; GE Healthcare Japan, Tokyo, Japan).
Diagnosis and treatment of HCC
Hepatocellular carcinoma was diagnosed based on an increasing course of α-fetoprotein as well as dynamic CT, 14 magnetic resonance imaging, 15 contrast-enhanced ultrasound with perflubutane (Sonazoid; Daiichi Sankyo, Tokyo, Japan), 16 and/or pathological findings. Tumornode-metastasis (TNM) stage as denoted in the 6th Report of the Liver Cancer Study Group of Japan was used for assessment of HCC stage. 17 When possible, all treatments were carried out following the Japanese practical guidelines for HCC. 18, 19 Written informed consent was obtained from all patients prior to treatment. The study protocol was in compliance with the Helsinki Declaration and approved by the Institutional Ethics Committee of Ehime Prefectural Central Hospital (No. 27-26).
Statistical analysis
Statistical analyses were undertaken using the KaplanMeier method with a log-rank test, Cox hazard analysis, Student's t-test, Welch's test, Mann-Whitney U-test, χ 2 -test, or Fischer's exact test as appropriate. Statistical significance was defined as P < 0.05. Statistical analyses were carried out using EZR version 1.32, which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). 20 Propensity matching was done with SPSS Statistics version 23 (SPSS Japan, Tokyo, Japan).
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RESULTS
T
HE CLINICAL CHARACTERISTICS of the analyzed patients are shown in Table 1 . Muscle volume loss and HCC within the Milan criteria were complicated in 15.6% and 34.1% in each group, respectively. Although serum albumin level and prothrombin time (PT, %) were significantly different between patients with and without PHT (3.53 ± 0.56 vs. 3.67 ± 0.69 g/dL and 77.7 ± 12.6% vs. 81.2 ± 17.1%; P = 0.035 and P = 0.031, respectively), Child-Pugh class did not show a significant difference. There were no significant differences in regard to the other clinical background factors examined (age, gender, serum AST, serum ALT, platelet count, serum total bilirubin, or etiology of CLD).
Although there was no significant difference in OS rate (OSR) between patients with and without MVL in the non-PHT group (P = 0.076, Holm's method), that of patients with MVL in the PHT group was lower compared to those without MVL in both the PHT and non-PHT groups (P = 0.017 and P = 0.012, respectively, Holm's method). There was no significant difference in OSR between patients with only PHT and those negative for both MVL and PHT (P = 1.000, Holm's method), or between patients with only MVL and those positive for both MVL and PHT (P = 1.000, Holm's method) (Fig. 1a) . There was also no significant difference between the PHT and non-PHT groups (P = 0.622) (Fig. 1b) (Fig. 1c) . In an additional subanalysis, after excluding patients with HCC, the result was the same. The OSR of patients with MVL (n = 36) was lower than that of those without (n = 192) (1-, 3-, and 5-year OSR: 85.9% vs. 98.9%, 72.8% vs. 93.5%, and 72.8% vs. 86.4%, respectively; P = 0.0014) (data not shown).
In univariate Cox hazard analysis, serum total bilirubin level (≥1.0 mg/dL) (hazard ratio [HR], 2.000; 95% CI, 1.229-3.256; P = 0.005), serum albumin level (≤3.5 g/dL) (HR, 1.878; 95% CI, 1.161-3.037; P = 0.010), Child-Pugh class B (HR, 2.477; 95% CI, 1.530-4.011; P < 0.001), positive for naïve HCC (within Milan criteria) (HR, 2.183; 95% CI, 1.290-3.690; P = 0.004), and positive for MVL (HR, 2.797; 95% CI, 1.601-4.885; P < 0.001) were significant prognostic factors for death. Furthermore, (Table 2) . There was a significant difference in regard to cause of death between patients with and without MVL (liver failure / HCC / digestive bleeding / others / unknown: 3/6/0/8/0 vs. 11/19/3/13/5; P = 0.016).
DISCUSSION
I
T IS WELL known that MVL is an important prognostic factor in CLD patients with or without HCC who are treated with resection 1 or transplantation. [2] [3] [4] [5] Notably, with progression of CLD grade, the ratio of patients with MVL has also been reported to increase. 7, 8 Portal hypertension as a major complication of LC and EGV frequently develops in patients with LC along with progression of hepatic fibrosis. In Japan, EIS and EVL are used for treatment of esophageal varices, and a previous report found no significant difference between those in regard to prevention of variceal bleeding. 21 As for gastric varices, BRTO has also been shown effective, with a 5-year bleeding rate of only 1.5%. 13 However, few studies have elucidated the clinical importance of MVL in LC patients with PHT.
In the present study, the OSR of patients with both MVL and PHT was lower than that of those without MVL in both the PHT and non-PHT groups (P = 0.017 and P = 0.012, respectively, Holm's method). In our cohort, MVL was an independent prognostic factor for death in LC patients, whereas PHT was not. Although the cause of death in patients without MVL was digestive bleeding in three and unknown in five, the frequency of death from other organ complications was greater in those with MVL. Additional analyses will be needed to elucidate the role of MVL in the clinical course of CLD patients, especially those with PHT. Figure 1 Overall survival of liver cirrhosis patients with and without muscle volume loss (MVL) and portal hypertension (PHT). (a) There was no significant difference for overall survival rate (OSR) between patients with and without MVL in the non-PHT group (P = 0.076, Holm's method). However, the OSR of patients with both MVL and PHT (1-, 3-, and 5-year OSR: 96.1%, 61.8%, and 34.4%, respectively) was worse compared to those without MVL in both the PHT and non-PHT groups (98.4%, 85.7%, and 71.4%, and 97.9%, 87.0%, and 78.1% respectively; P = 0.017, P = 0.012, respectively, Holm's method). (b) There were no significant differences in OSR between the PHT and non-PHT groups (1-, 3-, and 5-year OSR: 97.3% vs. 96.3%, 82.1% vs. 84.2%, and 64.9% vs. 73.0%, respectively; P = 0.622). (c) There was a significant difference in OSR between patients with and without MVL (1-, 3-, and 5-year OSR: 89.1% vs. 98.1%, 69.0% vs. 86.4%, and 35.8% vs. 74.1%, respectively; P < 0.001).
Recent progress in antiviral therapy, such as direct-acting antivirals 22, 23 and nucleos(t)ide analogs, [24] [25] [26] has made prevention of CLD progression possible, although issues related to muscle wasting in CLD patients remain. It is also well known that many LC patients have protein-calorie malnutrition, 27, 28 and it has been reported that a late evening snack (LES) may be useful for improving protein catabolism and lipolysis. 29 Also, the combination of in-hospital exercise and consumption of branched-chain amino acid (BCAA) granules was found to minimize skeletal muscle atrophy compared with in-hospital exercise alone during treatment of HCC in CLD patients. 30 Therefore, nutrition with a LES should be considered for LC patients undergoing treatment for EGV as well as those with MVL status. In our previous report, we found that walking an additional 2000 steps per day and consumption of LES comprised of BCAA granules before bed were useful for improving muscle volume and function in LC patients. 31 Sarcopenia has been defined as MVL and reduced muscle strength. 32, 33 The relationship between MVL and reduced muscle strength, and the influence not only of MVL but also that of reduced muscle strength for the prognosis of CLD patients should be investigated in a future study. In addition, establishment of an effective strategy for treating progression of MVL and reduced muscle strength in CLD patients is needed.
The present study has some limitations, including its retrospective nature. Also, additional studies will be needed for obtaining more certain conclusions with a greater number of patients. Nevertheless, we found that MVL and HCC were significant independent prognostic factors in LC patients both with and without PHT. 
